medigraphic.com
ISSN 1527-3172 (Electronic)

2022, Number 2

<< Back Next >>

MEDICC Review 2022; 24 (2)

Lymphocyte Subsets in Defense Against New Pathogens in Patients with Cancer

Arango-Prado MC, Villegas-Valverde CA, Torres-López G, Soto-Pardeiro P, Suárez-Reyes A, Faxas-García ME, Diéguez-Rodríguez V, Gracia-Medina E, Esperón-Noa R, del Castillo-Bahi R, Méndez-Rosabal A, Curbelo-Alfonso L

Language: English
References: 55
Page: 26-34
PDF size: 339.92 Kb.


ABSTRACT

INTRODUCTION Immunity in cancer patients is modified both by the cancer itself and by oncospecific treatments. Whether a patient’s adaptive immunity is impaired depends on their levels of naive lymphocytes and other cell populations. During the COVID-19 pandemic, cancer patients are at greater risk of progressing to severe forms of the disease and have higher mortality rates than individuals without cancer, particularly while they are receiving cancer-specific therapies. An individual’s protection against infection, their response to vaccines, and even the tests that determine the humoral immune response to SARS-CoV-2, depend on lymphocyte populations, meriting their study.
OBJECTIVE Estimate blood concentrations of lymphocytes involved in the immune response to new pathogens in cancer patients.
METHODS We carried out an analytical study of 218 cancer patients; 124 women and 94 men, 26–93 years of age, who were treated at the National Oncology and Radiobiology Institute in Havana, Cuba, March–June, 2020. Patients were divided into five groups: (1) those with controlled disease who were not undergoing cancer-specific treatment; (2) those undergoing debulking surgery; (3) patients undergoing chemotherapy; (4) patients undergoing radiation therapy and (5) patients currently battling infection. We evaluated the following peripheral blood lymphocyte subpopulations via flow cytometry: B lymphocytes (total, naive, transitional, memory, plasmablasts and plasma cells); T lymphocytes (total, helper, cytotoxic and their respective naive, activated, central memory and effector memory subsets); and total, secretory and cytotoxic natural killer cells and T natural killer cells. We also estimated neutrophil/lymphocyte ratios. Lymphocyte concentrations were associated with controlled disease and standard cancer therapy. For variables that did not fall within a normal distribution, ranges were set by medians and 2.5–97.5 percentiles. The two-tailed Mann–Whitney U test was used to measure the effect of sex and to compare lymphocyte subsets. We calculated odds ratios to estimate lymphopenia risk.
RESULTS All cancer patients had lower values of naive helper and cytotoxic T lymphocyte populations, naive B lymphocytes, and natural killer cells than normal reference medians. Naive helper T cells were the most affected subpopulation. Memory B cells, plasmablasts, plasma cells, activated T helper cells, and cytotoxic central memory T cells were increased. Patients undergoing treatment had lower levels of naive lymphocytes than untreated patients, particularly during radiation therapy. The risk of B lymphopenia was higher in patients in treatment. The odds ratio for B lymphopenia was 8.0 in patients who underwent surgery, 12.9 in those undergoing chemotherapy, and 13.9 in patients in radiotherapy.
CONCLUSIONS Cancer and conventional cancer therapies significantly affect peripheral blood B lymphocyte levels, particularly transitional T helper lymphocytes, reducing the immune system’s ability to trigger primary immune responses against new antigens.


REFERENCES

  1. Au L, Boos LA, Swerdlow A, Byrne F, ShepherdS, Fendler A, et al. Cancer, COVID-19,and antiviral immunity: The CAPTUREStudy. Cell. 2020 Oct 1;183(1):4–10.https://doi.org/10.1016/j.cell.2020.09.005

  2. Zheng Y, Chen Y, Yu K, Yang Y, Wang X, YangX, et al. Fatal infections among cancer patients:a population based study in the United States.Infect Dis Ther. 2021 Jun;10(2):871–95. https://doi.org/10.1007/s40121-021-00433-7

  3. Bakouny Z, Hawley JE, Choueiri TK, Peters S,Rini BI, Warner JL, et al. COVID-19 and cancer:current challenges and perspectives. CancerCell. 2020 Nov 9;38(5):629–46. https://doi.org/10.1016/j.ccell.2020.09.018

  4. Li H, Baldwin E, Zhang X, Kenost C, Luo W, CalhounEA, et al. Comparison and impact of COVID-19 for patients with cancer: a survival analysis offatality rate controlling for age, sex and cancer type.BJM Health Care Inform. 2021 May;28(1):e100341.https://doi.org/10.1136/bmjhci-2021-100341

  5. Lee LYW, Cazier JB, Starkey T, Briggs SE,Arnold R, Bisht V, et al. COVID-19 prevalenceand mortality in patients with cancer and theeff ect of primary tumour subtype and patientdemographics: a prospective cohort study. LancetOncol. 2020 Oct;21(10):1309–16. https://doi.org/10.1016/ S1470-2045(20)30442-3

  6. Johannesen1 JB, Smeland S, Aaserud S,Buanes EA, Skog A, Ursin G, et al. COVID-19in cancer patients, risk factors for diseases andadverse outcome, a population-based study fromNorway. Front Oncol. 2021 Mar 25;11:652535.https://doi.org/10.3389/fonc.2021.652535

  7. Zong Z, Wei Y, Ren J, Zhang L, Zhou F. Theintersection of COVID-19 and cancer: signalingpathways and treatment implications.Mol Cancer. 2021 May 17;20(1):76.https://doi.org/10.1186 / s12943-021-01363-1

  8. Zheng H, Rao AM, Dermadi D, Toh T, Jones LM,Donato M, et al. Multi-cohort analysis of host immuneresponse identifi es conserved protective and detrimentalmodules associated with severity acrossviruses. Immunity. 2021 Apr 13;54(4):753–68.https://doi.org/10.1016/j.immuni.2021.03.002

  9. De Clercq E, Li G. Approved antiviral drugsover the past 50 years. Clin Micobiol Rev.2016;29(3):695–747. https://doi.org/10.1128/CMR.00102-15

  10. Conry SJ, Milkovich KA, Yonkers NL, RodriguezB, Bernstein HB, Asaad R, et al. Impaired plasmacytoiddendritic cell (PDC)-NK cell activity inviremic human immunodefi ciency virus infectionattributable to impairments in both PDC andNK cell function. J Virol. 2009;83(21):11175–87.https://doi.org/10.1128/JVI.00753-09

  11. Naumenko V, Turk M, Jenne CN, Kim SJ. Neutrophilin viral infection. Cell Tissue Res. 2018Mar;371(3):505–16. https://doi.org/10.1007/s00441-017-2763-0

  12. Orakpoghenor O, Avazi DO, Markus TP, OlaoluOS. Lymphocytes: a brief review. Sci J ImmunolImmunother. 2019 Jun 24;3(1):004–008. https://doi.org/10.37871/sjii.id17

  13. Alhalabia O, Lyer S, Vivek S. Testing for COVID-19 in patients with cancer. EClinicalMedicine.2020 May 3;23:e100374. https://doi.org/10.1016/j.eclinm.2020.100374

  14. Derosa L, Melenotte C, Griscelli F, Gachot B, MarabelleA, Kroemer G, et al. The immuno-oncological challengeof COVID-19. Nat Cancer. 2020;1(10):946–64.https://doi.org/10.1038/s43018-020-00122-3

  15. Liu T, Zeng G, Tao H, Shi Y; COVID CancerPatients Research Group, Wang T, et al. Lowprevalence of IgG antibodies to SARS-CoV-2in cancer patients with COVID19. Int J Cancer.2020 Dec 1;147(11):3267–9. https://doi.org/10.1002./ijc33148

  16. Solodky ML, Galvez C, Russias B, Detourbet P,N’Guyen-Bonin V, Herr AL, et al. Lower detectionrates of SARS-COV2 antibodies in cancer patientsversus health care workers after symptomaticCOVID-19. Ann Oncol. 2020 Aug;31(8):1087–88.https://doi.org/10.1016/j.annonc.2020.04.475

  17. Bejanyan N, Brunstein CG, Cao Q, Lazaryan A,Luo X, Curtsinger J, et al. Delayed immune reconstitutionafter allogeneic transplantation increasesthe risks of mortality and chronic GVHD.Blood Adv. 2018 Apr 24;2(8):909–22. https://doi.org/10.1182/bloodadvances.2017014464

  18. Tau N, Shargian-Alon L, Reich S, Paul M,Gaff ter A, Shepshelovich D, et al. Reportinginfections in clinical trials of patients with haematologicalmalignancies. Clin Microbiol Infect. 2019Dec;25(12):1494–500. https://doi.org/10.1016/j.cmi.2019.04.029

  19. Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, LeeKH, et al. Optimal timing of infl uenza vaccinationduring 3-week cytotoxic chemotherapy cycles.Cancer. 2017 Mar 1;123(5):841–48. https://doi.org/10.1002/cncr.30468

  20. Jamshed S, Walsh EE, Dimitroff LJ, SeguinSantelli J, Falsey AR. Improved immunogenicityof high-dose infl uenza vaccine compared tostandard-dose infl uenza vaccine in adult oncologypatients younger than 65 years receivingchemotherapy: a pilot randomized clinical trial.Vaccine 2016 Jan 27;34(5):630–5. https://doi.org/10.1016/j.vaccine.2015.12.037

  21. National Comprehensive Cancer Network.Preliminary recommendations of the NCCNCOVID-19 Vaccination Advisory Committee.Version 1.0 1/22/2021. Pennsylvania: NationalComprehensive Cancer Network (NCCN);2021 Jan 22 [cited 2021 Feb 2]. 7 p. Availableat: https://merkelcell.org/wp-content/uploads/2021/01/COVID-19_Vaccination_Guidance_V1.0.pdf

  22. Maecker HT, McCoy JP, Nussenblatt R. Standardizingimmunophenotyping for the HumanImmunology Project. Nat Rev Immunol. 2012 Feb17;12(3):191–200.

  23. Kokuina E, Breff -Fonseca MC, Villegas-ValverdeCA, Mora-Díaz I. Normal values of T, Band NK lymphocytes subpopulations in peripheralblood of healthy Cuban adults. MEDICCRev. 2019 Apr–Jul;21(2–3):16–21. https://doi.org/10.37757/MR2019.V21.N2-3.5

  24. Bisset LR, Lung TL, Kaelin M, Ludwig E, DubsRW. Reference values for peripheral blood lymphocytephenotypes applicable to the healthyadult population in Switzerland. Eur J Haematol.2004 Mar;72(3):203–12.

  25. Morbach H, Eichhorn EM, Liese JG, Girschick HJ.Reference values for B cell subpopulations frominfancy to adulthood. Clin Exp Immunol. 2010Nov;162(2):271–9. https://doi.org/10.1111/j.1365-2249.2010.04206.x

  26. World Medical Association. Declaration of Helsinki:ethical principles for medical research involvinghuman subjects. JAMA [Internet]. 2013 Nov 27 [cited2021 Jun 2]; 310(20):2191–4. Available at: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2013.281053

  27. Vargas-Camaño ME, Guido-Bayardo RL, Martínez-Aguilar NE, Castrejón-Vázquez MI. [Canceras secondary immunodefi ciency. Review]. RevAler Mex. 2016 Apr–Jun;63(2):169–79. https://doi.org/10.29262/ram.v63i2.176. Spanish.

  28. Litterman AJ, Zellmer DM, Grinnen KL, HuntMA, Dudek AZ, Salazar AM, et al. Profoundimpairment of adaptive immune responses byalkylating chemotherapy. J Immunol. 2013 Jun15;190(12):6259–68. https://doi.org/10.4049/jimmunol.1203539

  29. Verma R, Foster RE, Horgan K, Mounsey K,Nixon H, Smalle N, et al. Lymphocyte depletionand repopulation after chemotherapy for primarybreast cancer. Breast Cancer Res. 2016 Jan26;18(1):10. https://doi.org/10.1186/s13058-015-0669-x

  30. Lv Y, Song M, Tian X, Yv X, Liang N, Zhang J.Impact of radiotherapy on circulating lymphocytesubsets in patients with esophageal cancer. Medicine(Baltimore). 2020 Sep 4;99(36):e20993.https://doi.org/10.1097/MD.0000000000020993

  31. Dovšak T, Ihan A, Didanovič V, Kansky A, VerdenikM, Hren NI. Eff ect of surgery and radiotherapyon complete blood count, lymphocyte subsets andinfl ammatory response in patients with advancedoral cancer. BMC Cancer. 2018 Mar 1;18(1):235.https://doi.org/10.1186/s12885-018-4136-9

  32. Hogan BV, Peter MB, Shenoy HG, Horgan K,Hughes TA. Surgery induced immunosuppression.Surgeon. 2011 Feb;9(1):38–43. https://doi.org/10.1016/j.surge.2010.07.011

  33. Das RK, Vernau L, Grupp SA, Barrett DM. NaiveT-cell defi cits at diagnosis and after chemotherapyimpair cell therapy potential in pediatric cancers. Cancer Discov. 2019 Apr;9(4):492–9.https://doi.org/10.1158/2159-8290.CD-18-1314

  34. Chen X, Lowe M, Herliczek T, Hall MJ,Danes C, Lawrence DA, et al. Protectionof normal proliferating cells against chemotherapyby Staurosporine-Mediated,selective, and reversible G1 arrest. J NatlCancer Inst. 2000 Dec 20;92(24):1999–2008.https://doi.org/10.1093/jnci/92.24.1999

  35. Jia Y, Xu L, Lin Q, Zhu M, Ding L, Wu K, et al.Levels of lymphocyte subsets in peripheral bloodprior treatment are associated with aggressivebreast cancer phenotypes or subtypes.Med Oncol. 2014 Jun;31(6):981. https://doi.org/10.1007/s12032-014-0981-9

  36. Vahidi Y, Bagheri M, Ghaderi A, Faghih Z.CD8-positive memory T cells in tumor- draininglymph nodes of patients with breast cancer.BMC Cancer. 2020 Mar 20(1);20:257. https://doi.org/10.1186/s12885-020-6714-x

  37. Zhu W, Germain C, Liu Z, Sebastian Y, DeviP, Knockaert S, et al. A high density of tertiarylymphoid structure B cells in lung tumors isassociated with increased CD4C T cell receptorrepertoire clonality. Oncoimmunology. 2015 Jun1;4(12):e1051922. https://doi.org/10.1080/2162402X.2015.1051922

  38. Falcke SE, Rühle PF, Deloch L, Fietkau R, FreyB, Gaipl US. Clinically relevant radiation exposurediff erentially impacts forms of cell death inhuman cells of the innate and adaptive immunesystem. Int J Mol Sci. 2018 Nov 13;19(11):3574.https://doi.org/10.3390/ijms19113574

  39. Lahoz-Beneytez J, Elemans M, Zhang Y, AhmedR, Salam A, Block M, et al. Human neutrophilkinetics: modeling of stable isotope labelingdata supports short blood neutrophil half-lives.Blood. 2016 Jun 30;127(26):3431–38. https://doi.org/10.1182/blood-2016-03-700336

  40. Cupp MA, Cariolou M, Tzoulaki I, Aune D, EvangelouE, Berlanga-Taylor AJ. Neutrophil to lymphocyteratio and cancer prognosis: an umbrellareview of systematic reviews and meta-analysesof observational studies. BMC Med. 2020 Nov20;18(1):360. https://doi.org/10.1186/s12916-020-01817-1

  41. Waidhauser J, Schuh A, Trepel M, SchmälterAK, Rank A. Chemotherapy markedly reducesB cells but not T cells and NK cells in patientswith cancer. Cancer Immunol Immunother.2020 Jan;69(1):147–57. https://doi.org/10.1007/s00262-019-02449-y

  42. Gustafson CE, Jadhav R, Cao W, Qi Q, PegramM, Tian L, et al. Immune cell repertoires in breastcancer patients after adjuvant chemotherapy. JCIInsight. 2020 Feb 27;5(4):e134569. https://doi.org/10.1172/jci.insight.134569

  43. Swanson GP, Jhavar SG, Hammonds K. The eff ectof pelvic radiation alone on lymphocyte subgroups.Clin Transl Radiation Oncol. 2020 May 30;23:100–2.https://doi.org/10.1016/j.ctro.2020.05.010

  44. Das RK, O’Connor RS, Grupp SA, DM Barrett.Lingering eff ects of chemotherapy on mature Tcells impair proliferation. Blood Adv. 2020 Oct13;4(19):4653–64. https://doi.org/10.1182/bloodadvances.2020001797

  45. Blair PA, Norena LY, Flores-Borja F, RawlingsDJ, Isenberg DA, Ehrenstein MR, et al.CD19(+)CD24(hi)CD38(hi) B cells exhibitregulatory capacity in healthy individuals butare functionally impaired in systemic lupuserythematosus patients. Immunity. 2010 Jan29;32(1):129–40. https://doi.org/10.1182/bloodadvances.2020001797

  46. Napoletano C, Bellati F, Landi R, Pauselli S,Marchetti C, Visconti V, et al. Ovarian cancercytoreduction induces changes in T cell populationsubsets reducing immunosuppression. J CellMol Med. 2010 Dec;14(12):2748–59. https://doi.org/10.1111/j.1582-4934.2009.00911.x

  47. Hogan BV, Peter MB, Shenoy HG, Horgan K,Hughes TA. Surgery induced immunosuppression.Surgeon. 2011 Feb;9(1):38–43. https://doi.org/10.1016/j.surge.2010.07.011

  48. Jiménez-Sánchez A, Memon D, Pourpe S, VeeraraghavanH, Li Y, Vargas HA, et al. Heterogeneoustumor-immune microenvironments amongdiff erentially growing metastases in an ovariancancer patient. Cell. 2017 Aug 24;170(5):927–38.https://doi.org/10.1016/j.cell.2017.07.025

  49. Tavakkoli M, Wilkins CR, Mones JV, MauroMJ. A novel paradigm between leukocytosis,G-CSF secretion, neutrophil-to-lymphocyte ratio,myeloid-derived suppressor cells, and prognosisin non-small cell lung cancer. Front Oncol.2019 Apr 26;9:295. https://doi.org/10.3389/fonc.2019.00295

  50. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y,et al. Immune phenotyping based on the Neutrophil-to-Lymphocyte Ratio and IgG level predictsdisease severity and outcome for patients withCOVID-19. Front Mol Biosci. 2020 Jul 3;7:157.https://doi.org/10.3389/fmolb.2020.00157

  51. Zengin E, Sarper N. Humoral immunity to diphtheria,tetanus, measles, and hemophilus infl uenzatype b in children with acute lymphoblasticleukemia and response to re-vaccination. PediatrBlood Cancer. 2009 Dec;53(6):967–72. https://doi.org/10.1002/pbc.22135

  52. Top KA, Vaudry W, Morris SK, Pham-Huy A, PernicaJM, Tapiéro B, et al. Waning vaccine immunityand vaccination responses in children treatedfor acute lymphoblastic leukemia: a Canadianimmunization research network study. Clin InfectDis 2020 Dec 3;71(9):e439–48. https://doi.org/10.1093/cid/ciaa163

  53. Blanchette PS, Chung H, Pritchard KI, Earle CC,Campitelli MA, Buchan SA, et al. Infl uenza vaccineeff ectiveness among patients with cancer:a population-based study using health administrativeand laboratory testing data from Ontario,Canada. J Clin Oncol. 2019 Oct 20;37(30):2795–804. https://doi.org/10.1200/JCO.19.00354

  54. ESMO [Internet]. Geneva: ESMO; c2021. COVID-19 and Cancer. ESMO statements for vaccinationagainst COVID-19 in patients with cancer;2020 Dec 22 [updated 2021 Apr 27; cited 2021 Feb2]. Available at: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination

  55. Desai A, Gainor JF, Hegde A, Schram AM,Curigliano G, Pal S, et al. COVID-19 vaccineguidance for patients with cancer participatingin oncology clinical trials. Nat Rev Clin Oncol.2021 May;18(5):313–9. https://doi.org/10.1038/s41571-021-00487-z




2020     |     www.medigraphic.com